1. Market Research
  2. > Healthcare
  3. > Blood Supply, Tissue Banking and Transplantation Market Trends
  4. > Heart Transplantation - Pipeline Review, H2 2013

Heart Transplantation - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 49 pages

Heart Transplantation - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Heart Transplantation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Heart Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Transplantation. Heart Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Heart Transplantation.
- A review of the Heart Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Heart Transplantation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Heart Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Heart Transplantation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Heart Transplantation - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heart Transplantation Overview 6
Therapeutics Development 7
Pipeline Products for Heart Transplantation - Overview 7
Pipeline Products for Heart Transplantation - Comparative Analysis 8
Heart Transplantation - Therapeutics under Development by Companies 9
Heart Transplantation - Pipeline Products Glance 10
Early Stage Products 10
Heart Transplantation - Products under Development by Companies 11
Heart Transplantation - Companies Involved in Therapeutics Development 12
Merck and Co., Inc. 12
Astellas Pharma Inc. 13
Portola Pharmaceuticals, Inc. 14
Viron Therapeutics, Inc. 15
NasVax Ltd. 16
ToleroTech Inc. 17
Heart Transplantation - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Assessment by Therapeutic Class 29
Drug Profiles 32
VT-111a - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Anti-CD3 Mab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
JAK3 Specific Inhibitors - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
AS-2521780 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
siRejection - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
JAK-3/1 Inhibitors - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
SCH-546738 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Heart Transplantation - Recent Pipeline Updates 41
Heart Transplantation - Dormant Projects 43
Heart Transplantation - Product Development Milestones 44
Featured News and Press Releases 44
Aug 22, 2013: Drug Application Filed for Additional Form of Immunosuppressant, “Cellcept Powder for Oral Suspension 32%” 44
Apr 23, 2013: US Files Healthcare Fraud Lawsuit Against Novartis For Orchestrating Multi-Million Dollar Prescription Drug Kickback Scheme 44
May 16, 2011: Chugai Pharma Files Application Seeking Japanese Approval For Pediatric Dosage And Administration Of CellCept 45
May 04, 2011: Argos Therapeutics´ Immunotherapy Platform Based On Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation 46
Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49



List of Tables

Number of Products under Development for Heart Transplantation, H2 2013 7
Number of Products under Development for Heart Transplantation - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Development, H2 2013 10
Products under Development by Companies, H2 2013 11
Heart Transplantation - Pipeline by Merck and Co., Inc., H2 2013 12
Heart Transplantation - Pipeline by Astellas Pharma Inc., H2 2013 13
Heart Transplantation - Pipeline by Portola Pharmaceuticals, Inc., H2 2013 14
Heart Transplantation - Pipeline by Viron Therapeutics, Inc., H2 2013 15
Heart Transplantation - Pipeline by NasVax Ltd., H2 2013 16
Heart Transplantation - Pipeline by ToleroTech Inc., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 24
Number of Products by Stage and Route of Administration, H2 2013 26
Number of Products by Stage and Molecule Type, H2 2013 28
Number of Products by Stage and Therapeutic Class, H2 2013 31
Heart Transplantation Therapeutics - Recent Pipeline Updates, H2 2013 41
Heart Transplantation - Dormant Projects, H2 2013 43



List of Figures

Number of Products by Top 10 Target, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 25
Number of Products by Stage and Top 10 Route of Administration, H2 2013 26
Number of Products by Top 10 Molecule Type, H2 2013 27
Number of Products by Stage and Top 10 Molecule Type, H2 2013 28
Number of Products by Top 10 Therapeutic Class, H2 2013 29
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 30



Companies Mentioned

Merck and Co., Inc.
Astellas Pharma Inc.
Portola Pharmaceuticals, Inc.
Viron Therapeutics, Inc.
NasVax Ltd.
ToleroTech Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
TransMedics, Inc. - Product Pipeline Analysis, 2016 Update

TransMedics, Inc. - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • July 2016
  • by Global Data

Summary TransMedics, Inc. (TransMedics) is a medical device company that develops organ transplant systems. The company offers product organ care systems that is used by surgeons in heart transplants and ...

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • October 2016
  • by Global Markets Direct

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hematopoietic Stem Cell Transplantation - ...

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016’, provides an overview of the Graft Versus ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.